- Home
- CERS
CERS
Cerus Corporation
as 05-20-2024 4:00pm EST
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
| Founded: | 1991 | Country: | United States |
| Employees: | N/A | City: | CONCORD |
| Market Cap: | 362.4M | IPO Year: | 1997 |
| Target Price: | $3.25 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.17 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.21 - $3.08 | Next Earning Date: | 05-02-2024 |
| Revenue: | $191,716,000 | Revenue Growth: | 4.32% |
| Revenue Growth (this year): | 3.4% | Revenue Growth (next year): | 12.41% |
Share on Social Networks:
Stock Insider Trading Activity of Cerus Corporation (CERS)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Swisher Daniel N JR | CERS | Director | May 9 '24 | Buy | $1.88 | 2,500 | $4,688.75 | 107,045 | SEC Form 4 |
| Witney Frank | CERS | Director | May 9 '24 | Buy | $1.89 | 20,000 | $37,800.00 | 180,059 | SEC Form 4 |
| Jayaraman Vivek K | CERS | Chief Operating Officer | Mar 12 '24 | Sell | $2.06 | 26,247 | $53,990.08 | 905,447 | SEC Form 4 |
| Jayaraman Vivek K | CERS | Chief Operating Officer | Mar 12 '24 | Sell | $1.97 | 26,794 | $52,902.07 | 878,653 | SEC Form 4 |
| Benjamin Richard J | CERS | Chief Medical Officer | Mar 12 '24 | Sell | $2.06 | 17,377 | $35,744.49 | 477,350 | SEC Form 4 |
| Benjamin Richard J | CERS | Chief Medical Officer | Mar 12 '24 | Sell | $1.97 | 17,738 | $35,021.91 | 459,612 | SEC Form 4 |
| Benjamin Richard J | CERS | Chief Medical Officer | Mar 8 '24 | Sell | $2.40 | 29,378 | $70,457.26 | 478,061 | SEC Form 4 |
| BJERKHOLT ERIC | CERS | Director | Dec 13 '23 | Buy | $1.62 | 10,000 | $16,200.00 | 142,133 | SEC Form 4 |
Latest Cerus Corporation News
CERS Breaking Stock News: Dive into CERS Ticker-Specific Updates for Smart Investing
Simply Wall St.
16 days ago
Cerus First Quarter 2024 Earnings: EPS Misses Expectations
Insider Monkey
17 days ago
Cerus Corporation (NASDAQ:CERS) Q1 2024 Earnings Call Transcript
Thomson Reuters StreetEvents
17 days ago
Q1 2024 Cerus Corp Earnings Call
GuruFocus.com
18 days ago
Cerus Corp (CERS) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ...
GuruFocus.com
18 days ago
Cerus Corp (CERS) Q1 2024 Earnings: Revenue Surpasses Estimates, Net Loss Narrows
Associated Press Finance
18 days ago
Cerus: Q1 Earnings Snapshot
Business Wire
18 days ago
Cerus Corporation Announces First Quarter 2024 Financial Results
Business Wire
a month ago